Berlin - Delayed Quote EUR

Exelixis Inc (EX9.BE)

31.53

+0.12

+(0.38%)

At close: January 31 at 8:01:01 AM GMT+1

Here's Why Exelixis (EXEL) is a Strong Value Stock

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Zacks 2 days ago

EXEL
Repligen (RGEN) Surges 3.7%: Is This an Indication of Further Gains?

Repligen (RGEN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Zacks 3 days ago

RGEN

EXEL
Exelixis to Release Fourth Quarter and Full Year 2024 Financial Results on Tuesday, February 11, 2025

ALAMEDA, Calif., January 28, 2025--Exelixis, Inc. (Nasdaq: EXEL) announced today that its fourth quarter and full year 2024 financial results will be released on Tuesday, February 11, 2025 after the markets close. At 5:00 p.m. ET / 2:00 p.m. PT, Exelixis management will host a conference call and webcast to discuss the results and provide a general business update. Access to the event is available via the Internet from the company’s website.

Business Wire 3 days ago

EXEL
Exelixis (EXEL) Earnings Expected to Grow: Should You Buy?

Exelixis (EXEL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks 3 days ago

EXEL
Exelixis Stock Falls as Oppenheimer Downgrades Rating to Perform

EXEL loses 5% after Oppenheimer downgrades its rating to Perform from Outperform on concerns about the potential differentiation of pipeline candidate zanzalintinib versus cabozantinib following the abstract for STELLAR-001 study.

Zacks 4 days ago

EXEL
Exelixis Announces Results from Subgroup Analysis of Phase 3 CABINET Pivotal Study Evaluating Cabozantinib in Advanced Gastrointestinal Neuroendocrine Tumors Presented at ASCO GI 2025

ALAMEDA, Calif., January 24, 2025--Exelixis, Inc. (Nasdaq: EXEL) today announced results from a subgroup analysis of the phase 3 CABINET pivotal study of patients with extra-pancreatic neuroendocrine tumors (epNET) arising in the gastrointestinal (GI) tract. The analysis showed cabozantinib was associated with an improvement in progression-free survival (PFS) compared with placebo in patients with advanced GI neuroendocrine tumors (NET), which was a subgroup of the epNET cohort. These results ar

Business Wire 7 days ago

EXEL
Exelixis Stock Faces a Reality Check: Will It Hit $41 or Drop to $33?

A major downgrade, a billion-dollar pipeline gamble, and a patent war--Exelixis investors brace for a wild ride.

GuruFocus.com 7 days ago

EXEL
Exelixis Stock Falls as Oppenheimer Downgrades Over Drug Differentiation Concerns

Oppenheimer shifts to a neutral stance on Exelixis, questioning differentiation between zanzalintinib and cabozantinib

GuruFocus.com 7 days ago

EXEL
Revenues, Treatment Pipeline Driving Exelixis Higher

Shares of oncology company Exelixis, Inc. (EXEL) gaining on rising revenue, pipeline progress.

FX Empire 9 days ago

EXEL
EXEL vs. TECH: Which Stock Is the Better Value Option?

EXEL vs. TECH: Which Stock Is the Better Value Option?

Zacks 10 days ago

EXEL
What Makes Exelixis (EXEL) an Investment Bet?

Riverwater Partners, an investment management company, released its “Sustainable Value Strategy” Q4 2024 investor letter. A copy of the letter can be downloaded here. The strategy outperformed its benchmark, the Russell 2500 Value Index, over the past year. The relative outperformance was mainly driven by positive stock selection while allocation effect also contributed positively. The […]

Insider Monkey 10 days ago

EXEL
4 PEG-Based Value Stocks to Neutralize Trump 2.0-Led Market Volatility

Here are four PEG-driven value stocks, WFC, EXEL, DAL and GBX, which qualify our screening criteria.

Zacks 10 days ago

GBX

EXEL

DAL
Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks 11 days ago

EXEL
Should You Be Adding Exelixis (NASDAQ:EXEL) To Your Watchlist Today?

It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...

Simply Wall St. 11 days ago

EXEL
BeiGene Stock Meets 80-Plus RS Rating Benchmark

BeiGene stock just hit that mark, with a jump from 69 to 84 Wednesday. Is BeiGene Stock A Buy? BeiGene stock reclaimed its 50-day moving average on Tuesday and is working on a consolidation with a 248.16 entry.

Investor's Business Daily 16 days ago

BEIGF

ONC

HALO
Zacks Industry Outlook Highlights Incyte, BioMarin, Exelixis, Halozyme and Blueprint Medicines

Incyte, BioMarin, Exelixis, Halozyme and Blueprint Medicines have been highlighted in this Industry Outlook article.

Zacks 17 days ago

BMRN

INCY

HALO
BridgeBio Pharma Stock Earns 87 RS Rating

BridgeBio Pharma stock saw a positive improvement to its Relative Strength (RS) Rating on Tuesday, with an increase from 64 to 87. Is BridgeBio Pharma Stock A Buy? BridgeBio Pharma earns the No. 180 rank among its peers in the Medical-Biomed/Biotech industry group.

Investor's Business Daily 17 days ago

CPRX

HALO

BBIO
Why Exelixis (EXEL) is Poised to Beat Earnings Estimates Again

Exelixis (EXEL) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Zacks 17 days ago

EXEL
5 Biotech Stocks Worth Adding to Your Portfolio in 2025

New drug approvals and pipeline progress are likely to help maintain the momentum for the Zacks Biomedical and Genetics industry despite the uncertain macro environment. A strong portfolio and solid pipeline progress position INCY, BMRN, EXEL, HALO and BPMC well in this volatile sector.

Zacks 17 days ago

HALO

BMRN

EXEL
Exelixis Provides Preliminary 2024 Results and Outlook for 2025

EXEL reports preliminary 2024 revenues. The company also provides guidance for 2025 and other pipeline updates.

Zacks 18 days ago

EXEL

Performance Overview

Return	EX9.BE	S&P 500
YTD	-1.22%	+2.26%
1-Year	+57.77%	+22.65%
3-Year	+102.96%	+36.30%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Exelixis Inc (EX9.BE)

Here's Why Exelixis (EXEL) is a Strong Value Stock

Repligen (RGEN) Surges 3.7%: Is This an Indication of Further Gains?

Exelixis to Release Fourth Quarter and Full Year 2024 Financial Results on Tuesday, February 11, 2025

Exelixis (EXEL) Earnings Expected to Grow: Should You Buy?

Exelixis Stock Falls as Oppenheimer Downgrades Rating to Perform

Exelixis Announces Results from Subgroup Analysis of Phase 3 CABINET Pivotal Study Evaluating Cabozantinib in Advanced Gastrointestinal Neuroendocrine Tumors Presented at ASCO GI 2025

Exelixis Stock Faces a Reality Check: Will It Hit $41 or Drop to $33?

Exelixis Stock Falls as Oppenheimer Downgrades Over Drug Differentiation Concerns

Revenues, Treatment Pipeline Driving Exelixis Higher

EXEL vs. TECH: Which Stock Is the Better Value Option?

What Makes Exelixis (EXEL) an Investment Bet?

4 PEG-Based Value Stocks to Neutralize Trump 2.0-Led Market Volatility

Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio

Should You Be Adding Exelixis (NASDAQ:EXEL) To Your Watchlist Today?

BeiGene Stock Meets 80-Plus RS Rating Benchmark

Zacks Industry Outlook Highlights Incyte, BioMarin, Exelixis, Halozyme and Blueprint Medicines

BridgeBio Pharma Stock Earns 87 RS Rating

Why Exelixis (EXEL) is Poised to Beat Earnings Estimates Again

5 Biotech Stocks Worth Adding to Your Portfolio in 2025

Exelixis Provides Preliminary 2024 Results and Outlook for 2025

Performance Overview